patient subgroup...
adolescents (typically 12-15 years of age) adults (typically between 18 and 65yr) age >= 55 yr age >= 60 yr age >= 65 yr age >= 75 yr alpha variant (B.1.1.7, UK) any cancer autoimmune disease beta variant (B.1.351 / 501Y.V2, South Africa) children corticosteroids: no corticosteroids: yes critical disease delta variant (B.1.617.2, Indian) dialysis patients elderly (typically over 65yr) fully vaccinated gamma variant (P.1, Brazil) haematological cancers healthcare workers immunodepression invasive ventilation kidney transplant recipients no oxygen needed non invasive oxygen obese omicron variant BA.1 (B.1.1.529) omicron variant BA.2 VOC original (Wuhan) strain positive for SARS-Cov-2 at baseline severe disease solid cancer solid organ transplant recipients subjects at risk
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
potential COVID-19 treatments - versus standard of care - for COVID-19 mild to moderate
method
abbreviations
Outcome
Relative effect 95%CI
LoD
Trt. better when
I2
k (RCT/OBS)
Bayesian probability
Overall ROB
Publication bias
Degree of certainty
Endpoint importance
Published MA
00 death D28 0.74 [0.49, 1.12]< 1 7% 9 studies (9/-) 92.1 % high not evaluable low crucial - death or transfer to ICU 0.89 [0.59, 1.34]< 1 46% 2 studies (2/-) 71.8 % high not evaluable low crucial - deaths 0.79 [0.59, 1.06]< 1 0% 21 studies (21/-) 94.3 % some concern low moderate crucial - deaths (time to event analysis only) 0.64 [0.28, 1.48]< 1 0% 3 studies (3/-) 85.1 % some concern not evaluable moderate crucial - clinical deterioration 0.81 [0.62, 1.07]< 1 13% 11 studies (11/-) 93.1 % some concern low moderate important - clinical improvement 1.28 [1.07, 1.54]> 1 38% 13 studies (13/-) 99.6 % some concern low moderate important - clinical improvement (14-day) 1.17 [0.93, 1.47]> 1 35% 9 studies (9/-) 91.6 % some concern not evaluable moderate important - clinical improvement (21-day) 2.09 [0.04, 119.96]> 1 0% 1 study (1/-) 63.7 % NA not evaluable important - clinical improvement (28-day) 1.47 [1.06, 2.04]> 1 59% 4 studies (4/-) 99.0 % some concern not evaluable moderate important - clinical improvement (7-day) 1.39 [1.12, 1.74]> 1 39% 8 studies (8/-) 99.8 % some concern not evaluable moderate important - clinical improvement (time to event analysis only) 1.24 [1.02, 1.50]> 1 54% 7 studies (7/-) 98.6 % some concern not evaluable moderate important - death or ventilation 0.59 [0.34, 1.02]< 1 0% 1 study (1/-) 97.0 % NA not evaluable important - hospital discharge 1.26 [0.70, 2.25]> 1 72% 3 studies (3/-) 77.9 % some concern not evaluable moderate important - mechanical ventilation 0.83 [0.49, 1.40]< 1 39% 9 studies (9/-) 75.4 % some concern serious moderate important - mechanical ventilation (time to event analysis only) 0.06 [0.01, 0.83]< 1 0% 1 study (1/-) 98.2 % NA not evaluable important - radiologic improvement (14-day) 1.82 [0.95, 3.51]> 1 39% 4 studies (4/-) 96.4 % some concern not evaluable moderate important - radiologic improvement (7-day) 0.40 [0.02, 6.97]> 1 77% 3 studies (3/-) 26.9 % some concern not evaluable moderate important - viral clearance 1.65 [1.15, 2.39]> 1 59% 11 studies (11/-) 99.7 % some concern low moderate important - viral clearance (time to event analysis only) 1.15 [0.86, 1.53]> 1 47% 3 studies (3/-) 82.7 % some concern not evaluable moderate important - viral clearance by day 14 0.81 [0.11, 6.01]> 1 94% 8 studies (8/-) 42.0 % some concern not evaluable moderate important - viral clearance by day 7 1.62 [1.13, 2.31]> 1 74% 9 studies (9/-) 99.6 % some concern not evaluable moderate important - ICU admission 0.98 [0.69, 1.39]< 1 0% 4 studies (4/-) 54.5 % some concern not evaluable moderate non important - recovery 1.15 [0.99, 1.33]> 1 0% 2 studies (2/-) 96.4 % some concern not evaluable moderate non important - 00 serious adverse events 0.72 [0.45, 1.16]< 1 0% 11 studies (11/-) 91.0 % some concern critical moderate important - acute kidney injury 1.18 [0.44, 3.18]< 1 0% 1 study (1/-) 37.2 % NA not evaluable non important - adverse events 1.64 [1.27, 2.12]< 1 41% 14 studies (14/-) 0.0 % some concern low moderate non important - arrhythmia 2.24 [0.23, 21.69]< 1 0% 1 study (1/-) 24.5 % NA not evaluable non important - elevated liver enzymes 3.48 [1.40, 8.64]< 1 0% 1 study (1/-) 0.4 % NA not evaluable non important - long QT 9.79 [1.27, 75.50]< 1 0% 1 study (1/-) 1.5 % NA not evaluable non important - renal impairment 1.35 [0.47, 3.86]< 1 0% 1 study (1/-) 28.8 % NA not evaluable non important - 00 Thromboembolic events 0.89 [0.31, 2.55]< 1 0% 1 study (1/-) 58.6 % NA not evaluable non important -
LoD: level of statistical demonstration:
